Evofosfomide potentiates the efficacy of a novel anti-PD-L1/PD-L2 monoclonal antibody against immune excluded tumors (SITC 2023) - Sep 27, 2023 - Abstract #853; Pres time: Nov 3, 2023; 09:00 AM - 07:00 PM; Location: Exhibit Hall B; "Background Evofosfamide (Evo) is a hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard...1 Moreover, in a phase 1 clinical trial, the combination of Evo with the anti-CTLA-4 Ipilimumab resulted in objective responses in patients with cold tumors...Conclusions These data indicate that Evo and IMGS-001 in combination improves upon the efficacy of either treatment alone, and those improvements are not observed for Evo in combination with anti-PD-1 treatment. This novel combination treatment will continue to be tested in preclinical models and has potential to be tested in a clinical trial."
Clinical • Melanoma • Oncology • Solid Tumor • PD-L2
|
|
Ahmad Salameh1; Paul Blezinger1; Christine Gagliardi1; Matt Hemberger1; James Barlow1; Michael Curran2; Federica Pericle1
|